Opendata, web and dolomites

NO-GO SIGNED

NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NO-GO project word cloud

Explore the words cloud of the NO-GO project. It provides you a very rough idea of what is the project "NO-GO" about.

demonstrating    syndrome    made    sustainable    clinical    clinically    roi    efsa    million    iso    urinary    depression    prescription    claims    icelandic    expensive    archangelica    over    worldwide    interactions    oab    recommend    gmp    saga    sagapro    embarrassment    80    2021    vivo    75    complying    active    66    prevalence    north    impaired    precursor    preserving    validated    108    expansion    500    benefit    obtain    2005    minimizing    rates    21    treatments    market    improvement    performed    bladder    capacity    seize    starting    population    fine    natural    plant    save    business    patients    america    opportunity    social    leaves    characterization    natura    jobs    30    relaxing    iceland    effect    people    drugs    profits    dropout    bodies    urgency    internalize    safety    normal    tune    selling    trial    doctors    health    life    vitro    efficiency    prepared    age    healthcare    landscape    launched    too    extend    validation    angelica    16    nocturia    small    symptoms    ecosystem    gt    multiple    standards    formulation    anxiety    create    pharmacological    day    10    cultivating    psychological    regulate    mass   

Project "NO-GO" data sheet

The following table provides information about the project.

Coordinator
SAGANATURA EHF 

Organization address
address: SUDURHELLU 8
city: HAFNARFJORDUR
postcode: 221
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Total cost 2˙232˙470 €
 EC max contribution 1˙562˙729 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGANATURA EHF IS (HAFNARFJORDUR) coordinator 1˙562˙729.00

Map

 Project objective

Over Active Bladder (OAB) is a syndrome characterized by several urinary symptoms, like urgency and nocturia. Prevalence is >10% of the population, 500 million people worldwide, and increases with age (>30% over 75 years old). OAB has psychological consequences such as embarrassment, impaired social interactions, depression and anxiety. Current pharmacological treatments for OAB are associated with multiple side effects and 80% dropout rates within 1 year. At Saga Natura we have developed NO-GO, a natural product for improving OAB symptoms, made from the leaves of the Icelandic plant Angelica archangelica. NO-GO’s precursor SagaPro was launched on the market in 2005, becoming Iceland’s top-selling non-prescription urinary product. We have performed in vivo and in vitro characterization of SagaPro’s bladder relaxing effect and we have clinically validated SagaPro in a small-scale clinical trial on 66 OAB patients, demonstrating it’s efficiency and safety. In Phase 2 we want to fine-tune our formulation, increase and internalize our production capacity complying with ISO and GMP standards and extend our clinical validation. We will also regulate NO-GO through the EFSA to obtain health claims. This way we will be prepared for our product’s mass expansion in Europe and in North America starting in 2021. This project will create 21 new jobs and profits of €108 Million with ROI of 16.6 after 5 years on the market. End-users will benefit from improvement of symptoms, no side effects, and ability to lead a normal every day life. Doctors will be able to recommend NO-GO to their OAB patients, a product with no side effects, and healthcare bodies will save costs on expensive OAB prescription drugs with too high dropout rates. Finally, with our sustainable approach for cultivating Angelica archangelica we will seize this business opportunity while also preserving the Icelandic landscape, using natural resources and minimizing the impact to the ecosystem.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NO-GO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NO-GO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More